CURRENT KNOWLEDGE, ATTITUDE, AND PRACTICE PATTERNS AMONG UROLOGISTS REGARDING PROSTATE MAGNETIC RESONANCE IMAGING (MRI) AND MR TARGETED BIOPSY

A. Muthigi1, A. Sidana1, A. K. George1, M. Kongnyuy1, S. Valayil1, M. Maruf1, K. Hammerich1, L. Krane1, B. J. Wood2, P. A. Pinto1

1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
2 Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland

Introduction and Objective: Multiparametric MRI (mpMRI) and MR targeted biopsy have a growing role in the screening and evaluation of prostate cancer. Its acceptance in the urologic community has been steadily increasing. We aim to evaluate the current knowledge, attitude, and practice patterns of urologists regarding this new technique.

Methods: A brief online questionnaire was designed to collect information on knowledge, preferences, and practice patterns of urologists regarding prostate mpMRI and MR targeted biopsy. The survey was sent to the members of the Endourological Society (ES), European Association of Urology (EAU), and Society of Urologic Oncology (SUO). Data was collected in an anonymous manner.

Results: A total of 302 responses were received [ES: 175, EAU: 23, SUO: 104]. Mean age of the respondents was 48.5 (± 11.9) years, with 59.7% practicing urology for > 10 years and 68.9% practicing in an academic setting. The majority of respondents (83.6%) believe MR targeted biopsy to be moderately to extremely beneficial in the evaluation of prostate cancer. 85.7% of responders utilize prostate MR imaging in their practice, and 63% utilize MR targeted biopsy. Practicing in an academic setting (p = 0.005), fellowship training in urologic oncology (p = 0.004), performing more than 5 biopsies per month (p = 0.016), and doing more than 25 radical prostatectomies per month (p < 0.001) were associated with utilizing MR targeted biopsy. MRI-ultrasound fusion biopsy was the most commonly reported technique utilized for targeted biopsy (73.0%). The two most common settings for utilization of MR targeted biopsy include patients with history of prior negative biopsy (96.3%) and monitoring patients on active surveillance (72.5%). In those who do not utilize MR targeted biopsy, the principal reasons were lack of necessary infrastructure (64.1%) and prohibitive costs (48.1%). A large proportion of respondents (66.0%) consider the MR targeted biopsy technique to be “not difficult at all” or only “slightly difficult” to learn. Fellowship training in urologic oncology was associated (p = 0.014) with perceived lower difficulty in learning the MR targeted biopsy technique.

Conclusions: A majority of respondents to our survey seem to look favorably upon use of prostate MRI and MR targeted biopsy in clinical practice. These results provide further insight into current beliefs and practice patterns among urologists regarding this novel and potentially transformative technology.

Financial Funding: This research was supported by the Intramural Research Program of the National Institutes of Health (NIH), National Cancer Institute, Center for Cancer Research, and the Center for Interventional Oncology. NIH and Philips Healthcare have a cooperative research and development agreement. NIH and Philips share intellectual property in the field.

This research was also made possible through the National Institutes of Health Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and generous contributions to the Foundation for the NIH from Pfizer Inc., The Doris Duke Charitable Foundation, The Alexandria Real Estate Equities, Inc. and Mr. and Mrs. Joel S. Marcus, and the Howard Hughes Medical Institute, as well as other private donors. For a complete list, please visit the Foundation website at: http://fnih.org/work/education-training-0/medical-research-scholars-program